Abstract
Hepatitis B virus (HBV) infected hepatitis is the common infectious disease. In the World Conservative Estimate Plan, the number of persons chronically infected with HBV is more than 300 million. Current regimen of treatment is far from satisfactory, as it is associated with certain side effects and viral resistance capacity. Therefore, a serious attention has recently been paid to the design and development of new potent anti-HBV agents. A variety of drugs have been synthesized and screened for their anti-HBV effects. These include nucleosides, natural compounds, quinolines, benzodiazepines, indoles, etc. Many of them are in wide trend in current treatment regimen. In this review, we have presented the recent development on the design and development of all categories of HBV inhibitors studied.
Keywords: Anti-hepatitis B virus agents, nucleosides, quinolines, benzodiazepines, indoles, Anti-Hepatitis B, Virus, (HBV), STERIMOL parameter, surface antigen, nucleocapsid core antigen, pre-core antigen, HBV replication, DNA polymerase, DNA, RNA, Chronic Hepatitis, Active prophylaxis, Passive Immunization, Interferon, Immunomodulators, Adoptive Immune Transfer, Nucleoside Analogs, thrombocytopenia, anemia, DHBV, famciclovir, Sophora flavescens, X-ray analysis, Hypserpa nitida, Alisma orientalis, replication, Inhi-bition assay, BENZODIAZEPINESINDOL, lamivudine, (QSAR)
Current Medicinal Chemistry
Title: Design and Development of Anti-Hepatitis B Virus Agents
Volume: 17 Issue: 29
Author(s): S. Kaushik, S. P. Gupta and P. K. Sharma
Affiliation:
Keywords: Anti-hepatitis B virus agents, nucleosides, quinolines, benzodiazepines, indoles, Anti-Hepatitis B, Virus, (HBV), STERIMOL parameter, surface antigen, nucleocapsid core antigen, pre-core antigen, HBV replication, DNA polymerase, DNA, RNA, Chronic Hepatitis, Active prophylaxis, Passive Immunization, Interferon, Immunomodulators, Adoptive Immune Transfer, Nucleoside Analogs, thrombocytopenia, anemia, DHBV, famciclovir, Sophora flavescens, X-ray analysis, Hypserpa nitida, Alisma orientalis, replication, Inhi-bition assay, BENZODIAZEPINESINDOL, lamivudine, (QSAR)
Abstract: Hepatitis B virus (HBV) infected hepatitis is the common infectious disease. In the World Conservative Estimate Plan, the number of persons chronically infected with HBV is more than 300 million. Current regimen of treatment is far from satisfactory, as it is associated with certain side effects and viral resistance capacity. Therefore, a serious attention has recently been paid to the design and development of new potent anti-HBV agents. A variety of drugs have been synthesized and screened for their anti-HBV effects. These include nucleosides, natural compounds, quinolines, benzodiazepines, indoles, etc. Many of them are in wide trend in current treatment regimen. In this review, we have presented the recent development on the design and development of all categories of HBV inhibitors studied.
Export Options
About this article
Cite this article as:
Kaushik S., P. Gupta S. and K. Sharma P., Design and Development of Anti-Hepatitis B Virus Agents, Current Medicinal Chemistry 2010; 17 (29) . https://dx.doi.org/10.2174/092986710793176375
DOI https://dx.doi.org/10.2174/092986710793176375 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemotherapy and Cardiotoxicity in Hematologic Malignancies
Current Cancer Drug Targets Radiation-Induced Neuroinflammation and Radiation Somnolence Syndrome
CNS & Neurological Disorders - Drug Targets Epigenetic Variation and Customising Nutritional Intervention
Current Pharmacogenomics and Personalized Medicine Psychosocial Factors and Central Sensitivity Syndromes
Current Rheumatology Reviews Drug-Induced Thromboembolic Events in Patients with Malignancy
Cardiovascular & Hematological Disorders-Drug Targets Treatment of Disorders Characterized by Reversible Airway Obstruction in Childhood: are Anti-cholinergic Agents the Answer?
Current Pharmaceutical Design Novel Systemic Drugs for Cutaneous T-Cell Lymphoma
Recent Patents on Anti-Cancer Drug Discovery Probiotics/Prebiotics in Viral Respiratory Infections: Implication for Emerging Pathogens
Recent Patents on Biotechnology Strategies for Leukotriene Modulation in Dermatology: Even More Visionary Perspectives? An Update
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Behcets Syndrome: Literature Review
Current Rheumatology Reviews Pediatric Differentiated Thyroid Cancer: When to Perform Conservative and Radical Surgery
Current Pediatric Reviews Biomarkers and Osteosarcoma and IGF
Recent Patents on Biomarkers Should the Status of the Pathway Mediated by BRCA1 and BRCA2 be Evaluated Before Selecting Cancer Chemotherapy Drugs?
Current Pharmacogenomics Molecular Cytogenetics and Cytogenomics of Brain Diseases
Current Genomics Hereditary Papillary Renal Carcinoma Type I
Current Molecular Medicine Gene Delivery System: A Developing Arena of Study for the New Era of Medicine
Recent Patents on DNA & Gene Sequences Anti-Angiogenic Therapies for Children with Cancer
Current Cancer Drug Targets Genetics of Obesity: What have we Learned?
Current Genomics Editorial [Hot topic: New and Emerging Drug Targets for the Treatment of Hematological Malignancies (Guest Editors: Dr. Linda J. Bendall)]
Current Drug Targets Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells
Current Cancer Drug Targets